Abstract
Several important US Food and Drug Administration (FDA) approval decisions are expected in the fourth quarter of 2010. First, the Prescription Drug User Fee Act (PDUFA) date for a decision on the approvability of sodium oxybate (Rekinla; developed by Jazz Pharmaceuticals) for the treatment of fibromyalgia is 11 October.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
